Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $19.50

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given an average recommendation of “Moderate Buy” by the fourteen brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $19.50.

A number of research firms have recently issued reports on BCRX. Citizens Jmp dropped their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Wednesday, November 5th. Zacks Research lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. HC Wainwright lifted their price target on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 15th. Cantor Fitzgerald boosted their price target on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 15th. Finally, Royal Bank Of Canada decreased their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, January 30th.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 21,773 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.65, for a total value of $166,563.45. Following the sale, the insider directly owned 398,751 shares in the company, valued at approximately $3,050,445.15. This trade represents a 5.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 183,453 shares of company stock worth $1,330,965 over the last ninety days. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Deerfield Management Company L.P. boosted its stake in BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after acquiring an additional 7,477,000 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of BioCryst Pharmaceuticals by 2,103.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock worth $38,336,000 after purchasing an additional 4,084,403 shares in the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of BioCryst Pharmaceuticals by 152.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock valued at $21,266,000 after purchasing an additional 1,432,824 shares during the last quarter. Bank of America Corp DE boosted its position in shares of BioCryst Pharmaceuticals by 97.9% in the 2nd quarter. Bank of America Corp DE now owns 2,841,155 shares of the biotechnology company’s stock worth $25,457,000 after purchasing an additional 1,405,498 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of BioCryst Pharmaceuticals by 1,059.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,456,857 shares of the biotechnology company’s stock worth $13,053,000 after purchasing an additional 1,331,230 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $6.38 on Monday. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31. The business has a 50-day moving average price of $7.22 and a 200 day moving average price of $7.50. The company has a market capitalization of $1.34 billion, a P/E ratio of -127.60 and a beta of 0.83.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.